BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37468228)

  • 1. Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on
    Pérez-Aisa Á; Nyssen OP; Keco-Huerga A; Rodrigo L; Lucendo AJ; Gomez-Rodriguez BJ; Ortuño J; Perona M; Huguet JM; Núñez O; Fernandez-Salazar L; Barrio J; Lanas A; Iyo E; Romero PM; Fernández-Bermejo M; Gomez B; Garre A; Gomez-Camarero J; Lamuela LJ; Campillo A; de la Peña-Negro L; Dominguez Cajal M; Bujanda L; Burgos-Santamaría D; Bermejo F; González-Carrera V; Pajares R; Notari PA; Tejedor-Tejada J; Planella M; Jiménez I; Lázaro YA; Cuadrado-Lavín A; Pérez-Martínez I; Amorena E; Gonzalez-Santiago JM; Angueira T; Flores V; Martínez-Domínguez SJ; Pabón-Carrasco M; Velayos B; Algaba A; Ramírez C; Almajano EA; Castro-Fernandez M; Alcaide N; Sanz Segura P; Cano-Català A; García-Morales N; Moreira L; Mégraud F; O'Morain C; Calvet X; Gisbert JP
    Gut; 2023 Nov; 72(11):2031-2038. PubMed ID: 37468228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
    Pabón-Carrasco M; Keco-Huerga A; Castro-Fernández M; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Tepes B; Jonaitis L; Voynovan I; Lucendo AJ; Lanas Á; Martínez-Domínguez SJ; Almajano EA; Rodrigo L; Vologzanina L; Brglez Jurecic N; Denkovski M; Bujanda L; Abdulkhakov RA; Huguet JM; Fernández-Salazar L; Alcaide N; Velayos B; Silkanovna Sarsenbaeva A; Zaytsev O; Ilchishina T; Barrio J; Bakulin I; Perona M; Alekseenko S; Romano M; Gravina AG; Núñez Ó; Gómez Rodríguez BJ; Ledro-Cano D; Pellicano R; Bogomolov P; Domínguez-Cajal M; Almela P; Gomez-Camarero J; Bordin DS; Gasbarrini A; Kupčinskas J; Cano-Català A; Moreira L; Nyssen OP; Mégraud F; O'Morain C; Gisbert JP;
    United European Gastroenterol J; 2024 Feb; 12(1):122-138. PubMed ID: 38050339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
    Nyssen OP; Perez-Aisa A; Castro-Fernandez M; Pellicano R; Huguet JM; Rodrigo L; Ortuñ J; O ; Gomez-Rodriguez BJ; Pinto RM; Areia M; Perona M; Nuñez O; Romano M; Gravina AG; Pozzati L; Fernandez-Bermejo M; Venerito M; Malfertheiner P; Fernanadez-Salazar L; Gasbarrini A; Vaira D; Puig I; Megraud F; O'Morain C; Gisbert JP;
    United European Gastroenterol J; 2021 Feb; 9(1):38-46. PubMed ID: 33176617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
    Nyssen OP; Perez-Aisa A; Rodrigo L; Castro M; Mata Romero P; Ortuño J; Barrio J; Huguet JM; Modollel I; Alcaide N; Lucendo A; Calvet X; Perona M; Gomez B; Gomez Rodriguez BJ; Varela P; Jimenez-Moreno M; Dominguez-Cajal M; Pozzati L; Burgos D; Bujanda L; Hinojosa J; Molina-Infante J; Di Maira T; Ferrer L; Fernández-Salazar L; Figuerola A; Tito L; de la Coba C; Gomez-Camarero J; Fernandez N; Caldas M; Garre A; Resina E; Puig I; O'Morain C; Megraud F; Gisbert JP
    Helicobacter; 2020 Oct; 25(5):e12722. PubMed ID: 32656898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
    Nyssen OP; Vaira D; Pérez Aísa Á; Rodrigo L; Castro-Fernandez M; Jonaitis L; Tepes B; Vologzhanina L; Caldas M; Lanas A; Lucendo AJ; Bujanda L; Ortuño J; Barrio J; Huguet JM; Voynovan I; Lasala JP; Sarsenbaeva AS; Fernandez-Salazar L; Molina-Infante J; Jurecic NB; Areia M; Gasbarrini A; Kupčinskas J; Bordin D; Marcos-Pinto R; Lerang F; Leja M; Buzas GM; Niv Y; Rokkas T; Phull P; Smith S; Shvets O; Venerito M; Milivojevic V; Simsek I; Lamy V; Bytzer P; Boyanova L; Kunovský L; Beglinger C; Doulberis M; Marlicz W; Goldis A; Tonkić A; Capelle L; Puig I; Megraud F; Morain CO; Gisbert JP;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2243-2257. PubMed ID: 34954341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management.
    Tepes B; Brglez Jurecic N; Tepes K; Espada Sanchez M; Perez Nyssen O; O'Morain C; Mégraud F; Gisbert J
    Dig Dis; 2021; 39(4):318-324. PubMed ID: 33099549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Trends in the Management of Helicobacter pylori Infection in Serbia: Preliminary Results from the European Registry on H. pylori Management.
    Milivojevic V; Babic I; Kekic D; Rankovic I; Sagdati S; Panic N; Spasic IS; Krstic M; Milosavljevic T; Moreira L; Nyssen OP; Mégraud F; O' Morain C; Gisbert J
    Dig Dis; 2023; 41(3):377-386. PubMed ID: 37253341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg).
    Nyssen OP; Pérez-Aisa Á; Tepes B; Rodrigo-Sáez L; Romero PM; Lucendo A; Castro-Fernández M; Phull P; Barrio J; Bujanda L; Ortuño J; Areia M; Brglez Jurecic N; Huguet JM; Alcaide N; Voynovan I; María Botargues Bote J; Modolell I; Pérez Lasala J; Ariño I; Jonaitis L; Dominguez-Cajal M; Buzas G; Lerang F; Perona M; Bordin D; Axon T; Gasbarrini A; Marcos Pinto R; Niv Y; Kupcinskas L; Tonkic A; Leja M; Rokkas T; Boyanova L; Shvets O; Venerito M; Bytzer P; Goldis A; Simsek I; Lamy V; Przytulski K; Kunovský L; Capelle L; Milosavljevic T; Caldas M; Garre A; Mégraud F; O'Morain C; Gisbert JP;
    Helicobacter; 2020 Jun; 25(3):e12686. PubMed ID: 32173974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management.
    Gatta L; Nyssen OP; Fiorini G; Saracino IM; Pavoni M; Romano M; Gravina AG; Granata L; Pellicano R; Gasbarrini A; Di Leo A; Losurdo G; Franceschi F; Nardone G; Rocco A; Dore MP; Farinati F; Ghisa M; Bellini M; Holton J; Puig I; Vaira D; Borghi C; Mégraud F; O'Morain C; Gisbert JP
    United European Gastroenterol J; 2023 Feb; 11(1):103-113. PubMed ID: 36565017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Registry on
    Nyssen OP; Bordin D; Tepes B; Pérez-Aisa Á; Vaira D; Caldas M; Bujanda L; Castro-Fernandez M; Lerang F; Leja M; Rodrigo L; Rokkas T; Kupcinskas L; Pérez-Lasala J; Jonaitis L; Shvets O; Gasbarrini A; Simsek H; Axon ATR; Buzás G; Machado JC; Niv Y; Boyanova L; Goldis A; Lamy V; Tonkic A; Przytulski K; Beglinger C; Venerito M; Bytzer P; Capelle L; Milosavljević T; Milivojevic V; Veijola L; Molina-Infante J; Vologzhanina L; Fadeenko G; Ariño I; Fiorini G; Garre A; Garrido J; F Pérez C; Puig I; Heluwaert F; Megraud F; O'Morain C; Gisbert JP;
    Gut; 2021 Jan; 70(1):40-54. PubMed ID: 32958544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients.
    McNicholl AG; Bordin DS; Lucendo A; Fadeenko G; Fernandez MC; Voynovan I; Zakharova NV; Sarsenbaeva AS; Bujanda L; Perez-Aisa Á; Vologzhanina L; Zaytsev O; Ilchishina T; Coba C; Lasala JP; Alekseenko S; Modolell I; Molina-Infante J; Ruiz-Zorrilla Lopez R; Alonso-Galan H; Moreno NF; Hinojosa J; Santaella I; Varela P; Gonzalez-Cordero PL; Barrio J; Dominguez-Jimenez JL; Nuñez O; Alcedo J; Nyssen OP; Caldas M; Donday MG; Shvetz O; Megraud F; O'Morain C; Gisbert JP
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):89-98. PubMed ID: 30978536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow].
    Bordin DS; Voynovan IN; Embutnieks YV; Nyssen OP; Megraud F; O Morain C; Perez-Gisbert J
    Ter Arkh; 2020 Apr; 92(2):12-18. PubMed ID: 32598712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
    Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
    Zhang W; Chen Q; Liang X; Liu W; Xiao S; Graham DY; Lu H
    Gut; 2015 Nov; 64(11):1715-20. PubMed ID: 26338726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
    Chen Q; Zhang W; Fu Q; Liang X; Liu W; Xiao S; Lu H
    Am J Gastroenterol; 2016 Dec; 111(12):1736-1742. PubMed ID: 27670603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.